RxDoctor Payments Data

Leslie Caren, MD

Internal Medicine · Waterford, MINPI 1649288960

Payments from drug & device makers

$1,123in general payments, 2019–2025

Across 29 payments — averaging $38.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$533
  • Inspire Medical Systems, Inc.$210
  • Novo Nordisk$141
  • Biohaven Pharmaceuticals, Inc.$125
  • Pfizer$37
  • GSK$22
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$1,123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,123 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$72,142
Medicare patients
195
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide59$111,086
EliquisApixaban78$75,741
OzempicSemaglutide40$54,676
JardianceEmpagliflozin25$25,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,112
JanuviaSitagliptin Phosphate12$16,961
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$11,554
Repatha SureclickEvolocumab14$7,572
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$7,210
Pulmicort FlexhalerBudesonide15$5,872
Rosuvastatin Calcium225$4,573
Atorvastatin Calcium278$4,230
Incruse ElliptaUmeclidinium Bromide12$3,976
Losartan Potassium240$3,917
Novolog FlexpenInsulin Aspart12$3,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$75,74178 claims
Novo NordiskOzempic$141$54,67640 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$22$36,64351 claims
Boehringer IngelheimJardiance$12$25,89825 claims
MerckJanuvia$14$16,96112 claims
AstraZenecaPulmicort Flexhaler$533$5,87215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →